CommercialCoverageHigh impact
June 2026
SelectHealth·NV, ID, UT, CO · Psychiatry, Dermatology, Urology +3 more·Policy Bulletin
Effective date
Jun 1, 2026
We identified it
Jun 20, 2026
Summary
Select Health published 6 policy changes including 2 new policies and 4 revisions. Major changes include discontinuation of Spravato coverage for commercial plans, new hyoid suspension coverage criteria for sleep apnea, and removal of cystoscopy requirements for sacral nerve stimulation. Additionally, 25 new genetic testing policies are being incorporated.
Action Required
Immediately: Billing teams must review and update billing procedures for multiple policy changes. Stop billing Spravato medication and administration for Select Health Commercial plans effective 4/1/2026. Update prior authorization requirements for cellular/tissue-based products per Medicare guidelines. Remove cystoscopy documentation requirements for sacral nerve stimulation procedures. Prepare for implementation of 25 new genetic testing policies effective 6/1/2026. Review hyoid suspension procedures to ensure AirLift procedures are not billed as covered services.